A new Nature Medicine study shows that antibiotics' gut microbiome effects can last up to 8 years. The strongest signals come from clindamycin, fluoroquinolones, and flucloxacillin.

Gabriel Baldanzi of Uppsala University in Sweden led the work. The team drew on prescription records and stool data from 14,979 adults. The findings give doctors fresh reason to prescribe with care.

What the antibiotics gut microbiome study tracked

The team paired Swedish Prescribed Drug Register data with faecal data from Swedish biobanks. Each subject had a faecal metagenome on file.

The study left out anyone on antibiotics within 30 days. It also left out those with inflammatory bowel disease (IBD) and chronic lung disease. That kept the focus on long-tail effects, not short-term ones.

The most-prescribed drugs in the cohort were penicillin V, extended-spectrum penicillins, and tetracyclines.

The three drugs with the strongest fingerprint

After adjustment, drug use in the year before sampling was tied to the biggest drop in species count. Clindamycin, fluoroquinolones, and flucloxacillin hit hardest.

The species-richness numbers are stark.

• Each clindamycin course taken under 1 year before sampling cut species by 47.
• Each fluoroquinolones course cuts species by 20.
• Each flucloxacillin course cut species by 21.

Drugs taken 4 to 8 years before sampling tied to 10% to 15% altered species abundance. That is the long tail of the antibiotics gut microbiome story.

"We can see that antibiotic use as far back as 4-8 years ago is linked to the composition of a person's gut microbiome today," Baldanzi said in a press statement. "Even a single course of treatment with certain types of antibiotics leaves traces," he added.

Even a single course can mark the antibiotic gut microbiome

A sub-analysis covered 7,664 participants. It set 3,356 with one course, compared with 4,308 with no courses in the prior 8 years.

Single doses of tetracyclines, flucloxacillin, fluoroquinolones, clindamycin, sulfamethoxazole-trimethoprim, cephalosporins, or macrolides tied to lower species diversity. The link held for courses taken under 8 years before sampling. Age and sex did not change the signal.

Baldanzi flagged the flucloxacillin link as a surprise. "Flucloxacillin is considered a narrow-spectrum antibiotic with activity against a group of bacteria called Gram-positive bacteria," he said. "We need further studies to better understand the mechanisms behind this finding."

Drugs that left no signal

Not every drug class hit the gut for the long haul. No signal showed for extended-spectrum penicillins (pivmecillinam, sulfamethoxazole-trimethoprim), amoxicillin, or amoxicillin-clavulanic acid.

That gap matters for prescribing choices.

How the gut recovers — and when it stalls

The team also tracked the gut microbiome recovery of antibiotics. The fastest rebound came in the first 2 years after exposure. After that, it slowed sharply.

The recovery rate roughly tracked the size of the initial drop. Bigger hit, bigger early bounce-back, but never a full reset for some.

Baldanzi flagged one surprise. Species richness, the simple count of microbes in the gut, did not always come back. "This indicates that some bacterial species may be lost from the gut after treatment with certain antibiotics," he said.

What the outside experts say

Earlier work ties clindamycin, fluoroquinolones, and flucloxacillin to higher levels of microbes linked to higher BMI, serum triglycerides, and type 2 diabetes. Causation is not proven.

"We know that the composition of the gut microbiome often reflects a person's cardiometabolic health — cholesterol levels, glucose levels, and body fat," Baldanzi said. "Changes in the gut microbiome have also been described in gut conditions such as constipation and inflammatory bowel disease."

Whether antibiotic-driven shifts cause these conditions years later is still an open question, he added.

Adam Faye, MD, called the data important. Faye runs clinical research at NYU Langone Health's IBD Center in New York.

" That said, the notion that a single antibiotic course can influence microbiome composition for years to come is still remarkable," Faye told Medscape Medical News.

Faye's earlier work showed a higher IBD risk five years after an antibiotic course. He said an 8-year effect was not a shock in that context.

The antibiotics gut microbiome takeaway is not to skip the drugs. They remain lifesaving for bacterial infections. But where viral infection is likely or watchful waiting is appropriate, the antibiotics-gut microbiome data adds a reason to hold off.

Coverage on Medigear.uk shows why primary care, GI, and infection teams must track how new antibiotics' gut microbiome research shapes prescribing.

Source: Originating coverage based on Medscape Medical News reporting on the Nature Medicine study led by Gabriel Baldanzi of the Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Outside expert commentary from Adam Faye, MD, IBD Centre at NYU Langone Health, New York City.